Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 and Avelumab in Chemotherapy Resistant Pancreatic Cancer
NCT03481920Phase 1Terminated
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC). Primary endpoints: Objective Response Rate at 6 months and Safety Assessment. Started Jan 2018; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03481920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03481920.